Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 12/20 | 0.79 |
| ▸ | GABBR1 | Q9UBS5 | 12/20 | 0.79 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | CD38 | P28907 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | ULK1 | O75385 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3121907 | 0.89 | GABBR2 (1.00) | GABBR2GABBR1PDE10AAXLTYRO3 | |
| SCHEMBL3118358 | 0.88 | GABBR2 (1.00) | GABBR2GABBR1PDE10AAXLTYRO3 | |
| SCHEMBL3111419 | 0.88 | GABBR2 (1.00) | GABBR2GABBR1PDE10AAXLTYRO3 | |
| SCHEMBL3122477 | 0.77 | GABBR2 (0.78) | GABBR2GABBR1AXLTYRO3MERTK | |
| SCHEMBL3108316 | 0.76 | GABBR2 (1.00) | GABBR2GABBR1PDE10A | |
| SCHEMBL3119355 | 0.76 | GABBR2 (1.00) | GABBR2GABBR1 | |
| SCHEMBL3123795 | 0.76 | GABBR2 (1.00) | GABBR2GABBR1 | |
| SCHEMBL3119363 | 0.76 | GABBR2 (1.00) | GABBR2GABBR1 | |
| SCHEMBL3123805 | 0.76 | GABBR2 (1.00) | GABBR2GABBR1 | |
| SCHEMBL3119366 | 0.76 | GABBR2 (1.00) | GABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | DPYD, NUDT1, HPRT1 | GABBR2 1611/4885GABBR1 1499/4885MDM2 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.